Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 28, 2019; 25(8): 989-1001
Published online Feb 28, 2019. doi: 10.3748/wjg.v25.i8.989
Published online Feb 28, 2019. doi: 10.3748/wjg.v25.i8.989
Characteristics | Value |
Male sex (%) | 318/551 (55.7) |
Age at diagnosis, yr | 40.56 ± 16.11 |
BMI at diagnosis, kg/m2 | 22.28 ± 3.19 |
Family history of IBD (%) | 51/369 (13.8) |
History of smoking (%) | 77/443 (17.4) |
First symptom | |
Hematochezia | 388/548 (70.8) |
Diarrhea | 164/548 (29.9) |
Abdominal pain | 39/548 (7.1) |
Diagnostic interval, d (median) | 223.28 ± 483.15 (69) |
Time from first symptom to hospital visit, d (median) | 154.22 ± 379.140 (40) |
Time from first hospital visit to diagnosis, d (median) | 69.06 ± 295.04 (9) |
Mayo score at diagnosis (%) | |
Mild | 179/399 (44.9) |
Moderate | 204/399 (51.1) |
Severe | 220/399 (4.0) |
Disease extent at diagnosis (%) | |
Proctitis | 253/547 (46.3) |
Left side | 160/547 (29.3) |
Extensive | 134/547 (24.5) |
Steroid (oral or intravenous) use (%) | 250/551 (45.4) |
AZA/6MP use (%) | 163/551 (29.6) |
Anti-TNFα use (%) | 50/551 (9.1) |
Admission due to flare-up (%) | 121/430 (22.0) |
Frequent admission due to flare-up (%) | 50/551 (9.1) |
UC-related surgery (%) | 7/551 (1.3) |
Clinical remission at the latest follow-up (%) | 333/467 (71.3) |
- Citation: Kang HS, Koo JS, Lee KM, Kim DB, Lee JM, Kim YJ, Yoon H, Jang HJ. Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. World J Gastroenterol 2019; 25(8): 989-1001
- URL: https://www.wjgnet.com/1007-9327/full/v25/i8/989.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i8.989